menu Menu Search
What are you looking for? close
RCVS Registered: 7025700
Run by a qualified team of Vets
First Class Delivery only £3.99
Next Day Delivery available
Palladia - 50mg Palladia Tablets for Dogs - Per Tablet
View Larger

Palladia - 50mg Palladia Tablets for Dogs - Per Tablet

337523

£17.88

50mg Palladia for dogs works by targeting specific proteins involved in the growth and spread of cancerous cells. By inhibiting the activity of these proteins, the drug effectively halts tumour progression, allowing Palladia 50mg to attack cancerous cells while sparing the healthy ones.

This targeted approach minimises the overall side effects on your pet, making it a safer and more effective option for treating mast cell tumours.

Research and clinical trials have demonstrated the efficacy of 50mg Palladia for dogs in treating these tumours, with many cases showing significant tumour reduction and, in some instances, complete regression. This makes 50mg Palladia an essential treatment option for dogs battling mast cell tumours. Our emphasis on fast delivery ensures that your pet receives their Palladia promptly, giving them the best chance for a quick and successful recovery.

VET PRESCRIPTION REQUIRED

Product Features

add remove
  • Pack Size: - Sold Individually
  • Target Animal: - Dog (Canine)
  • Related Condition: - Mast cell tumours in dogs
  • Pet Prescription Required?: - Yes (For UK Orders)
  • Active Ingredient: - Toceranib Phosphate
  • Product Name: - 50mg Palladia Tablets for Dogs

More Information

add remove

Description

50mg Palladia Tablets for Dogs - Treatment for canine Mast Cell tumours

Palladia 50mg may only be supplied with a valid veterinary prescription issued by your vet. You should only purchase 50mg Palladia if you have or are in the process of arranging such a prescription. See information bar for further details.  

50mg Palladia tablets for dogs contain 50mg toceranib phosphate. Each Palladia tablet is round in shape, marked with the Pfizer logo on one side and the strength on the other. The 50mg Palladia tablet is red.

Palladia 50mg Tablets are used for the treatment of non-resectable Patnaik grade II (intermediate grade) or III (high grade), recurrent, cutaneous mast cell tumours in dogs.

Dosage and administration

For oral use.

Palladia tablets can be administered with or without food.

The initial recommended dose of Palladia for Dogs is 3.25 mg/kg bodyweight, administered every second day (see dosing table for details).

The dose given should be based on veterinary assessments conducted weekly for the first six weeks and, thereafter, every six weeks. Duration of treatment depends on the response to treatment.

Treatment should continue in the case of stable disease, or partial or complete response, provided that the product is sufficiently well tolerated. In case of tumour progression, treatment is unlikely to be successful and should be reviewed.

Dose adjustment/reduction

To manage adverse reactions, the dose of Palladia may be reduced to 2.75 mg/kg bodyweight or further to 2.25 mg/kg bodyweight administered every second day or treatment can be discontinued for up to two weeks (see Dose Adjustment table on the following page).

Contra-indications, warnings, etc

Do not use Palladia Tablets in pregnant or lactating bitches or in dogs intended for breeding.

Do not use Palladia in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use Palladia in dogs less than 2 years of age or less than 3 kg bodyweight.

Do not use in dogs with gastrointestinal bleeding.

For any mast cell tumour treatable by surgery, surgery should be the first choice of treatment.

Dogs should be carefully monitored. Dose reductions and/or dose interruptions may be needed to manage adverse events. Treatment with Palladia should be reviewed weekly for the first six weeks and every six weeks thereafter or at intervals deemed appropriate by the veterinarian. Evaluations should include assessment of clinical signs reported by the pet owner.

To appropriately use the dose adjustment table it is advised that a complete blood cell count, serum chemistry panel and urinalysis be conducted prior to initiation of treatment and approximately one month after treatment is initiated; thereafter at approximately six week intervals or as determined by the veterinarian. Periodic monitoring of laboratory variables should be completed in the context of the clinical signs and condition of the animal and results of laboratory variables at prior visits.

The safety of Palladia Tablets was evaluated in mast cell tumour-bearing dogs with the following:

Absolute neutrophil count > 1500/microlitre

Haematocrit > 25%

Platelet count > 75,000/microlitre

ALT or AST < 3x upper normal limit

Bilirubin < 1.25x upper normal limit

Creatinine < 2.5 mg/dl

Blood urea nitrogen < 1.5x upper normal limit

Palladia can cause vascular dysfunction which can lead to oedema and thromboembolism, including pulmonary thromboembolism. Discontinue treatment until clinical signs and clinical pathology have normalised. Before performing surgery, discontinue treatment for at least 3 days in order to assure vasculature homeostasis.

If systemic mastocytosis is present, standard pre-emptive care (e.g., H-1 and H-2 blockers) should be implemented prior to initiation of Palladia to avoid or minimize clinically significant mast cell degranulation and subsequent potentially severe systemic side effects.

Palladia has been associated with diarrhoea or gastrointestinal bleeding which may be severe and requires prompt treatment. Dose interruptions and dose reductions may be needed depending upon the severity of clinical signs.

In rare cases, serious and sometimes fatal gastrointestinal complications including gastrointestinal perforation occurred in dogs treated with Palladia. If gastrointestinal ulceration is suspected, whether or not due to Palladia or to mast cell tumour degranulation, stop the administration of Palladia and treat appropriately.

Toceranib is metabolised in the liver and in the absence of any studies on the effects of renal or hepatic impairment, should be used with caution in dogs suffering from hepatic disease.

Treatment should be permanently discontinued if severe adverse events recur or persist despite appropriate supportive care and dose reduction as described in the table on the following page.

No interaction studies have been performed with toceranib. No information relating to potential cross resistance with other cytostatic products is available.

As Palladia is eliminated to a large extent by metabolism in the liver, the combination with other drugs capable of inducing or inhibiting liver enzymes should be used with caution.

It is not known to what extent toceranib could affect the elimination of other drugs.

Use non-steroidal anti-inflammatory drugs with caution in conjunction with Palladia due to an increased risk of gastrointestinal ulceration or perforation.

Adverse reactions with Palladia

Results from the clinical field study involving 151 treated and placebo-treated dogs showed that the clinical signs of the disease (mast cell tumour) and treatment related adverse reactions are very similar in nature.

Very common (more than 1 in 10 animals)

Mild to moderate:

Diarrhoea, neutropenia, weight loss, blood in faeces/haemorrhagic diarrhoea/gastrointestinal bleeding, anorexia, lethargy, vomiting; lameness/musculoskeletal disorder, dehydration, dermatitis, pruritus; increased alanine aminotransferase, thrombocytopenia, decreased albumin, decreased haematocrit.

Common (more than 1 but less than 10 animals in 100 animals)

Severe:

Vomiting, diarrhoea, anorexia, lethargy, dehydration, pyrexia, blood in faeces/haemorrhagic diarrhoea/gastrointestinal bleeding, duodenal ulceration, nausea, septicaemia, skin necrosis, weight loss; increased alanine aminotransferase, decreased haematocrit.

Mild to moderate:

Localised or general pain, nausea, tachypnoea, polydipsia, flatulence, pyrexia, nasal depigmentation; changes in coat colour, alopecia, urinary tract infection; increased bilirubin, increased creatinine.

Uncommon (more than 1 but less than 10 animals in 1000 animals)

Severe lameness/musculoskeletal disorder.

Severe circulatory shock.

There were two deaths that were possibly treatment related. In one dog, pathology findings revealed vascular thrombosis with disseminated intravascular coagulopathy (DIC) and pancreatitis. The other dog died following gastric perforation.

There were two further deaths; however, relation to treatment could not be established.

Two dogs developed epistaxis that was not associated with thrombocytopenia. Another dog developed epistaxis with concurrent disseminated intravascular coagulopathy.

Three dogs had seizure-like activity; however, relation to treatment could not be established.

User warnings

Palladia may impair male and female fertility and embryo/foetal development. Avoid skin contact with the tablets, faeces, urine, and vomit of treated dogs. The tablets must be administered as a whole and should not be broken or ground. If a broken tablet is rejected by the dog after chewing, it should be disposed of. Wash hands thoroughly with soap and water following handling of the product, and disposing of vomit, urine, or faeces of treated dogs.

Pregnant women should not routinely administer Palladia, should avoid contact with faeces, urine and vomit from treated dogs and broken or moistened Palladia tablets.

Ingestion of Palladia may be harmful for children. Children must not come into contact with Palladia. Keep children away from faeces, urine or vomit of treated dogs.

Gastrointestinal discomfort such as vomiting or diarrhoea may occur if this drug is accidentally ingested. In the case of accidental ingestion, seek medical advice immediately and show Package Leaflet or label to the physician.

Pharmaceutical precautions

Do not use after the expiry date stated on the carton.

Palladia does not require any special storage conditions.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Keep out of the reach and sight of children.

For animal treatment only.

Legal category

Palladia is a POM-V (Pet Prescription Required)

You may also like

Vetmedin 5mg Flavour Tablet - per Tablet

Vetmedin 5mg Flavour Tablet - per Tablet

Vetmedin 5mg Flavour Tablets are used for the treatment of canine congestive heart failure in larger dogs originating from dilated cardiomyopathy or valvular insufficiency. VET PRESCRIPTION REQUIRED

£1.01
Palladia - 10mg Palladia Tablets for Dogs - Per Tablet

Palladia - 10mg Palladia Tablets for Dogs - Per Tablet

Palladia 10mg for Dogs - Treatment for Mast Cell Tumours in Dogs

Mast cell tumours are a prevalent type of cancer in dogs, responsible for a large portion of all canine skin tumors. These malignant growths develop from mast cells, a type of white blood cell. Early detection and appropriate treatment are crucial in managing this condition, and 10mg Palladia for dogs provides a highly effective solution.

10mg Palladia for dogs lies in its ability to target specific proteins involved in the growth and spread of cancerous cells. By inhibiting the activity of these proteins, Palladia effectively halts tumor progression. This targeted approach allows 10mg Palladia to attack the cancerous cells while sparing healthy ones, reducing the overall side effects on your dog.

How do 10mg Palladia Tablets Work?

The active substance in Palladia 10mg Tablets is toceranib phosphate. This compound belongs to a class of medicines known for their anticancer activity. Toceranib functions as a receptor-tyrosine-kinase inhibitor. In simpler terms, it blocks specific enzymes known as tyrosine kinases. These enzymes are found in mast-cell tumours and play a pivotal role in the growth and spread of cancer cells and the development of blood vessels. By inhibiting these enzymes, Palladia Tablets for Dogs can control abnormal cell growth and prevent the further progression of the tumour.

VET PRESCRIPTION REQUIRED

£4.97
Palladia - 15mg Palladia Tablets for Dogs - Per Tablet

Palladia - 15mg Palladia Tablets for Dogs - Per Tablet

15mg Palladia for Dogs - Treatment for Canine Mast Cell Tumours

Mast cell tumours, a common type of cancer in dogs, account for a large portion of all canine skin tumours. These malignant growths originate from mast cells, a type of white blood cell. Early detection and proper treatment are vital in managing this condition, and 15mg Palladia for dogs offers a highly effective solution.

Palladia 15mg for dogs works by targeting specific proteins involved in the growth and spread of cancerous cells. The drug inhibits the activity of these proteins, effectively stopping tumour progression. This targeted approach allows 15mg Palladia to attack cancerous cells while sparing healthy ones, minimising overall side effects on your pet.

VET PRESCRIPTION REQUIRED

£6.56